ロード中...
Synergistic antitumor effect of the anti-ErbB2 antibodies trastuzumab and H2-18 on trastuzumab-resistant gastric cancer cells
Trastuzumab resistance is a severe problem in the treatment of ErbB2-amplified cancer. Although trastuzumab plus pertuzumab is able to partly overcome trastuzumab resistance in ErbB2-overexpressing cancer, its antitumor efficacy remains limited. The present study investigated the antitumor activity...
保存先:
| 出版年: | Oncol Lett |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
D.A. Spandidos
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7988693/ https://ncbi.nlm.nih.gov/pubmed/33777223 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2021.12661 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|